Background {#Sec1}
==========

In a chemoprophylaxis setting, a number of anti-malarial drugs have been associated with neurological or psychiatric adverse events (NPAEs), in particular, the quinoline-methanol derivative mefloquine \[[@CR1]--[@CR4]\]. Although the mechanisms of such neurotoxicity are not always well understood or clearly defined, a considerable body of evidence has accumulated on this topic \[[@CR5]\]. Despite this, it can be difficult to translate pre-clinical neurotoxicity findings, generally observed at toxicological doses, into the potential for clinical neurological or psychiatric reactions in malaria patients or those receiving malaria chemoprophylaxis. Additionally, NPAEs may be readily confounded by neurological or psychiatric signs and symptoms of acute malaria and underlying risk factors for psychiatric conditions.

The 8-aminoquinoline, tafenoquine, has been approved as monotherapy for travellers' prophylaxis, with an approved dose of 200 mg/day for 3 days followed by a 200 mg weekly maintenance doses thereafter \[[@CR6], [@CR7]\]. Tafenoquine is the only once-weekly prophylaxis that can be used in areas with chloroquine- and mefloquine-resistant parasites. Tafenoquine can also provide an alternative weekly prophylaxis regimen to mefloquine, but potentially without the concerns regarding NPAEs that restrict mefloquine use \[[@CR4], [@CR8]\]. Thus, the NPAE profile of tafenoquine is of great clinical interest.

Tafenoquine has also been approved for *Plasmodium vivax* relapse prevention as a single-dose therapy (300 mg) in combination with the standard adult dose of chloroquine (1500 mg free base in staggered dosing over 3 days) \[[@CR9]--[@CR11]\]. Previously, the recommended treatment for *P. vivax* relapse prevention required 3-days of chloroquine plus 14-days of primaquine 15 mg or 30 mg once daily. Primaquine is also an 8-aminoquinoline, but adherence to the dosing schedule is poor, and the clinical effectiveness of unsupervised primaquine is similar to that of placebo \[[@CR12], [@CR13]\]. In contrast, single-dose tafenoquine offers the possibility of complete adherence and consistent clinical effectiveness \[[@CR9]--[@CR11]\]. Preventing clinical relapses associated with the re-activation of the dormant *P. vivax* hypnozoites would potentially have a significant impact on reducing the burden of malaria and accelerating *P. vivax* elimination in endemic countries. This review considers the available preclinical and clinical safety data to assess the potential for tafenoquine to induce NPAEs in the context of findings for other anti-malarial drugs.

CNS adverse events of marketed anti-malarial drugs {#Sec2}
==================================================

Preclinical evaluations {#Sec3}
-----------------------

Neurotoxicity is a complex area for preclinical investigation. In vitro studies of cytotoxicity against human neuroblastoma cells or similar models are suggestive of neurotoxic potential, but the relevance of such results depends on drug penetration into the CNS, as well as pharmacokinetic and other factors, for example, metabolic status. In animal models, cytotoxicity and morphological damage are obvious outcomes, but may be restricted to very specific brain areas. Neurological effects can also derive from purely functional disruption, with no morphological damage, for example, convulsions induced by fluoroquinolones \[[@CR14]--[@CR16]\]. Thus, in modern drug development, neurobehavioural testing is used to detect any functional effects of drugs. This uses both observational and more complex methods, and multiple tests must be used to objectively evaluate different potential functional and behavioural impacts of the drug.

For older anti-malarial drugs, comprehensive neurotoxicological preclinical testing may not have been conducted. However, for new agents, supra-therapeutic or lethal drug doses are administered in animal models to attempt to induce observable lesions in CNS tissues. If lethal doses do not induce neurotoxicity, then the toxicities that caused death are deemed dose limiting. In such circumstances, a "safety factor" (typically \> 10-fold) is applied to the pharmacokinetic exposures in animals in order to predict the "highest achievable exposure" for humans. Consequently, the absence of neurotoxicity findings in pre-clinical animal models at supra-therapeutic or lethal doses is reassuring evidence that neurotoxicity in humans will be unlikely if the plasma concentrations in animals are at least tenfold greater than those achieved in humans following therapeutic or prophylactic dosing.

Even if drugs have the potential for neurotoxicity in animal models at supra-therapeutic doses, if the human dosing regimen does not achieve pharmacodynamically relevant exposures, and if the safety margins with CNS toxicity in preclinical species are acceptable, then NPAEs should not be expected. For example, although artemisinins are neurotoxic in animal models \[[@CR17]--[@CR21]\], the rate of NPAEs with these agents in patients is very low (1.1%) and despite extensive use of artemisinins globally, NPAEs have not emerged as a significant safety concern \[[@CR5]\]. The pre-clinical studies were conducted at supra-therapeutic doses with long durations of exposure and in some cases an oil vehicle was used, which further increased artemisinin drug exposure \[[@CR22], [@CR23]\]. There is also evidence that higher exposures are needed to elicit neurotoxicity in primates versus rodents and dogs \[[@CR22]\]. In contrast, artemisinins for malaria treatment are given orally, for short durations and at low doses, generally resulting in human drug exposures that would not be expected to cause neurotoxicity \[[@CR24], [@CR25]\]. However, concerns still apply to certain populations where intrinsic factors may affect the pharmacokinetics of the drug. For example, oral dispersible artemether-lumefantrine at a dose of 20/120 mg twice daily for 3 days could not be recommended to treat infants weighing \< 5 kg with *P. falciparum* malaria, as the artemether and dihydroartemisinin exposures exceeded the preclinical neurotoxicity safety margins \[[@CR26]\]. Neurotoxicity may also limit the opportunity to increase artemisinin doses to overcome drug resistance \[[@CR24]\]. Note also that following frequent dosing with artesunate in severe malaria, dihydroartemisinin levels in cerebrospinal fluid increased with time while levels in plasma declined, indicating accumulation \[[@CR27]\]. Thus, NPAE risk depends on both the neurotoxic potential of a particular agent documented in preclinical studies and the pharmacokinetic/pharmacodynamic profile of the dosing regimen used.

Clinical adverse events {#Sec4}
-----------------------

The MedDRA preferred term classification system is the standard method for assigning adverse events (AEs) to drug treatments used in clinical trials. Two system organ classes are relevant for neuropsychiatric risk: neurological disorders and psychiatric disorders (Table [1](#Tab1){ref-type="table"}).Table 1MedDRA system organ classes relevant for assessment of drug-related neuropsychiatric riskNeurological disorders Peripheral neuropathies, headaches, nervous system neoplasms malignant and unspecified (NEC), spinal cord and nerve root disorders, congenital and peripartum neurological conditions, demyelinating disorders, nervous system neoplasms benign, increased intracranial pressure and hydrocephalus, movement disorders (incl. Parkinsonism), encephalopathies, seizures (incl. subtypes), mental impairment disorders, neurological disorders of the eye, cranial nerve disorders (excl. neoplasms), structural brain disorders, neuromuscular disorders, central nervous system infections and inflammations, sleep disturbances (incl. subtypes), central nervous system vascular disordersPsychiatric disorders This is currently based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) and includes changes in physical activity, eating disorders and disturbances, impulse control disorders NEC, cognitive and attention disorders and disturbances, dissociative disorders, somatic symptom and related disorders, sleep disorders and disturbances, psychiatric and behavioural symptoms NEC, disturbances in thinking and perception, schizophrenia and other psychotic disorders, adjustment disorders (incl. subtypes), communication disorders and disturbances, sexual dysfunctions, disturbances and gender identity disorders, developmental disorders NEC, suicidal and self-injurious behaviours NEC, dementia and amnestic conditions, deliria (incl. confusion), manic and bipolar mood disorders and disturbances, anxiety disorders and symptoms, mood disorders and disturbances NEC, personality disorders and disturbances in behaviour, depressed mood disorders and disturbances*NEC* not elsewhere classifiable

Numerous papers of neuropsychiatric risk following anti-malarial treatment or during prophylaxis have been published, reaching various conclusions and promoting conflicting hypotheses \[[@CR28]\]. It is important to note that, although case reports may act as flags for further investigation, on their own they cannot be accepted as evidence of a general drug-related neuropsychiatric effect, particularly for subjective symptoms.

A recent systematic meta-analysis of the published literature on 'mental and neurological manifestations' associated with anti-malarial drugs by Bitta et al. \[[@CR5]\] provides a rigorous evaluation of the available clinical evidence. Specific psychiatric and neurological symptoms were examined for six anti-malarial drug classes across studies of treatment and prophylaxis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Estimated median prevalence of NPAEs with anti-malarial prophylaxis (P), treatment (T) or combined prophylaxis and treatment (C) \[[@CR5]\]

It can be seen immediately that there is no relationship between the prevalence of pooled NPAEs and the class of anti-malarial, except perhaps for the artemisinins, where prevalence is low for both artemether and artesunate. The lowest pooled prevalence of NPAEs was with the 8-aminoquinoline primaquine and the antibiotic dapsone and the highest was noted for the antibiotic minocycline and the 4-aminoquinoline amodiaquine. It can also be seen that for some drugs (mefloquine, pyrimethamine, sulphadoxine), the prevalence of events is far higher in prophylaxis studies than during malaria treatment, whereas for other drugs (chloroquine, atovaquone, artemether, artesunate) there is little difference between prophylaxis and treatment, and for quinine, prevalence is higher during treatment than for prophylaxis. Thus, we can conclude that there is no clear pattern of predicting NPAEs based on class or clinical indication, but that the risk depends on the specific neurotoxic potential and pharmacokinetic/pharmacodynamic properties of the drug (i.e. whether toxicity is related to maximum drug concentrations or to cumulative exposure) under the different dosing regimens for treatment and prophylaxis.

The meta-analysis described above allows us to compare different drugs and identify outliers in treatment studies, which either by their nature or frequency, are suggestive of drug-related NPAEs. However, this introduces limitations in terms of making comparisons across different patient populations that may have different risk profiles for neuropsychiatric symptoms, be infected with different or multiple *Plasmodium* species, possess different immunity profiles, or have variations in transmission settings and socio-economic conditions that might affect non-drug related NPAE risk.

Confounding factors in evaluating NPAE risk {#Sec5}
===========================================

Malaria effects versus drug effects in patients {#Sec6}
-----------------------------------------------

Malaria itself can produce varied and sometimes severe neuropsychiatric symptoms, the most serious being associated with cerebral malaria, including abnormal behaviour, impairment of consciousness, seizures, coma, or other neurologic abnormalities \[[@CR29]\]. However, even in milder disease, symptoms commonly include high fever, headache, fatigue and confusion \[[@CR29], [@CR30]\]. Previous malaria episodes can also lead to long-term cognitive, behavioural and psychological symptoms \[[@CR31]--[@CR39]\]. Thus, evaluating the relative contributions of drug and disease to NPAEs following anti-malarial treatment is very difficult, and the same data can be interpreted differently, leading to a range of opinions.

In treatment studies, which are typically conducted across a single study population, the relative NPAE risk of a new anti-malarial versus the comparator is evaluated; the comparator is usually determined by the relevant National Malaria Treatment Guidelines. However, as most new anti-malarial drugs are administered in combination, the contribution of each component of the regimen to the incidence of adverse events cannot be determined. In the case of *P. vivax* relapse prevention, new drug regimens are compared to placebo/chloroquine or placebo/artemisinin-based combination therapy (ACT) or the standard-of-care primaquine/chloroquine or primaquine/ACT. Thus, any adverse event signals outside the frequencies observed with these comparators would be concerning.

Prophylaxis versus treatment {#Sec7}
----------------------------

Prophylaxis studies remove the confounding effect of malaria symptomatology and allow a placebo-controlled comparison with a reference group. However, the dosing regimens and drug pharmacokinetics in prophylaxis are very different to those for treatment. In treatment, higher doses are generally given over a shorter time period, usually no more than 3 days, with the possible risk of adverse events related to maximum concentrations achieved. In contrast, prophylaxis generally involves lower doses regularly administered over a protracted time period, often months, with the risk of adverse events secondary to drug accumulation. For example, in the Bitta et al. meta-analysis outlined above, the difference between the NPAE risk for mefloquine in prophylaxis (25%) versus treatment (1%) was stark (Fig. [1](#Fig1){ref-type="fig"}). The increased frequency of NPAEs with mefloquine in prophylaxis is likely derived from the specific pharmacokinetics of the drug during the prophylactic dosing regimen, i.e. its ability to cross the blood--brain barrier, distribute and accumulate into cerebral tissue \[[@CR40], [@CR41]\], combined with its underlying potential for neurotoxicity at high doses, as suggested in pre-clinical studies \[[@CR4], [@CR42]--[@CR44]\]. Drugs that do not accumulate following multiple dosing in prophylaxis may actually have a lower frequency of adverse events than during treatment, for example, quinine (Fig. [1](#Fig1){ref-type="fig"}). Thus, data from prophylaxis studies cannot be extrapolated to predict NPAE risk during malaria treatment or vice versa.

Underlying neuropsychiatric risk {#Sec8}
--------------------------------

The population that receives malaria treatment or prophylaxis may not have the same risk for neuropsychiatric symptoms as the general population. For example, as mentioned above, previous malaria can lead to ongoing psychiatric and behavioural issues \[[@CR31]--[@CR39]\]. Exposure to insecticides used for malaria prevention, including dichlorodiphenyltrichloroethane (DDT), and pesticides for crop protection in rural areas, have also been suggested as a source of neurotoxicity \[[@CR45]--[@CR47]\]. Poverty and malnutrition \[[@CR48]\], as well as population displacement and conflict can also predispose to neuropsychiatric events \[[@CR49]\], and are also risk factors for malaria \[[@CR50]\].

In the case of prophylaxis, travel poses a number of potential neurological risks. Changes to routine and situation can trigger neuropsychiatric symptoms, for example by disruption of normal circadian rhythms or separation from support networks \[[@CR51]\], as can certain foods and infections that travellers may be exposed to \[[@CR52], [@CR53]\].

The most controversial example of data generated on malaria prophylaxis is from studies in military personnel. Malaria is a serious risk to the operational effectiveness of a military force. Thus, there is a compelling motivation to identify the most suitable prophylactic agents for use in military deployments to malaria endemic regions. Moreover, malaria is a potentially fatal disease in non-immune individuals and long-term sequelae may afflict survivors. Even where studies have compared a non-immune military population deployed to a malaria endemic region against a 'control' of either an untreated resident population, or a non-deployed military population \[[@CR54]\], it is important to understand the different underlying risk for neuropsychiatric findings in the compared populations.

To evaluate NPAE risk in soldiers given anti-malarial prophylaxis (deployed or non-deployed, with or without combat), we must first understand the underlying neuropsychiatric risk in military personnel versus civilians or in deployed versus non-deployed military personnel. If military personnel have a greater underlying risk for neuropsychiatric events than the general population, then trying to determine which NPAEs are drug-related, potentially over several months of treatment, becomes problematic, particularly if the underlying risk increases with deployment, i.e. over the same period that anti-malarial prophylaxis is taken.

In general, examination of large military health databases indicates that serving military personnel are at greater risk of neuropsychiatric symptoms, particularly depression, post-traumatic stress disorder and other internalizing conditions than the civilian population \[[@CR55]--[@CR67]\]. This may result from a higher frequency of pre-enlistment mental health issues in military personnel, particularly soldiers, versus those who choose alternative occupations \[[@CR56], [@CR61], [@CR62]\]. Deployment itself, particularly if associated with combat, affects neuropsychiatric risk \[[@CR58], [@CR61], [@CR63]--[@CR66], [@CR68]--[@CR71]\]. Thus, it might be expected that NPAEs occur more frequently in military personnel than the general population because of a higher underlying incidence of neuropsychiatric disorders. However, it is also possible that a drug which is associated with rare NPAEs in the general population may elicit such events more frequently in a more vulnerable population with a greater prevalence of pre-existing mental health issues, and/or a population subjected to severe stress, such as war-like military deployment \[[@CR2], [@CR72]\]. It seems reasonable, therefore, that NPAE risk should be evaluated prospectively and separately in specific populations (travellers, malaria endemic residents, deployed military, non-deployed military), as the results cannot necessarily be extrapolated between these groups.

Tafenoquine pre-clinical neurotoxicity assessment {#Sec9}
=================================================

The activity--structure relationships for the 8-aminoquinolines have been studied, with methyl substitution at position 4 of the quinoline ring conferring protection against neurotoxicity \[[@CR73]\]. As tafenoquine is 4-methyl-substituted, neurotoxicity would not be anticipated a priori.

Several pre-clinical studies to assess the potential CNS effects of tafenoquine have been conducted, including histopathological assessments in single- and repeat-dose studies in mice, rats and dogs, and detailed assessments of both neurobehavioural function and neurohistopathology in both single- and repeat-dose studies in rats \[[@CR74]\]. Across these studies, there was no evidence of neurotoxicity with tafenoquine \[[@CR74]\]. Additionally, distribution of radiolabelled tafenoquine into rat brain following a single oral dose of up to 25 mg/kg showed poor penetration with brain concentrations of \< 1% of the dose and low concentrations relative to other body tissues/organs \[[@CR74]\].

A comprehensive battery of preclinical neurotoxicological tests has been conducted on tafenoquine at supra-therapeutic and lethal doses in rats \[[@CR75]\]. Briefly, the maximum tolerated single dose of tafenoquine in rats was identified as 500 mg/kg, with non-neurological toxicities (gastrointestinal and haematological) found to be dose limiting. Based on these findings, neurobehavioural, histopathologic and toxicokinetic studies were conducted using single doses of 125, 250 or 500 mg/kg tafenoquine or placebo \[[@CR75]\]. The standard functional observation battery was performed pre-test, 0.5, 3, 6, 24 and 48 h post-dose. Motor activity was assessed using the number of beam breaks observed, and at doses \> 9-fold higher than the clinical exposure, motor activity was reduced at 48 h following tafenoquine dosing \[[@CR75]\]. Across all other assessments, there were no significant findings with tafenoquine relative to control rats \[[@CR75]\]. Histopathological investigations were conducted in all animals dosed with 500 mg/kg. There was no evidence of any neuropathological changes in brain sections and no evidence of neurodegeneration or other morphological abnormalities \[[@CR75]\]. There were no abnormalities identified in the gracile nucleus, previously cited as a potential target for drug toxicity \[[@CR42], [@CR75]\]. In conclusion, using experiments in rats that conclusively demonstrated neurotoxicity with mefloquine \[[@CR42]\], there was no evidence of neurotoxicity with tafenoquine \[[@CR75]\].

Although no pre-clinical neurotoxicity experiments were conducted in primates, several pharmacokinetic/pharmacodynamic studies of tafenoquine were conducted in Rhesus macaques. These studies were overseen by certified veterinarians and there was no evidence of any neurobehavioural disturbance or clinical evidence of neurotoxicity \[[@CR76]--[@CR79]\].

Tafenoquine for *P. vivax* relapse prevention {#Sec10}
=============================================

High-dose tafenoquine monotherapy versus chloroquine/primaquine {#Sec11}
---------------------------------------------------------------

Tafenoquine was previously investigated as monotherapy in *P. vivax* relapse prevention \[[@CR80]\]. In a randomized, active-control, double-blind trial (Bangkok, Thailand), *P. vivax* patients were randomized to tafenoquine 400 mg once daily for 3 days (N = 46) or standard 1500 mg (base) total dose chloroquine given over 3 days plus primaquine 15 mg daily for 14 days (N = 24) \[[@CR80]\]. This high monotherapy dose was abandoned as it had slow clearance of malaria parasites coupled with an unacceptable rate of drug-induced methaemoglobinemia. Hence, the further clinical development of tafenoquine was conducted in combination with a blood schizonticide. In terms of NPAEs, headache and dizziness were more common in the tafenoquine monotherapy group versus chloroquine/primaquine (Fig. [2](#Fig2){ref-type="fig"}). Although this could conceivably be a drug-related nervous system adverse effect, the headache and dizziness were more likely caused by slow parasite clearance under tafenoquine monotherapy: malaria symptoms persisted for longer in this group versus the chloroquine/primaquine group (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR80]\].Fig. 2Neuropsychiatric adverse events occurring with high-dose tafenoquine monotherapy or chloroquine/primaquine versus *P. vivax* parasitaemia \[[@CR80]\]

High-dose tafenoquine/chloroquine {#Sec12}
---------------------------------

Initial studies of tafenoquine/chloroquine in *P. vivax* relapse prevention examined tafenoquine doses of 300 mg/day for 7 days, 600 mg/day for 3 days and 600 mg single dose compared to chloroquine plus primaquine 15 mg/day for 14 days (Table [2](#Tab2){ref-type="table"}) \[[@CR81]\]. Even at the highest tafenoquine dose (2100 mg cumulative), NPAEs occurred less frequently overall than with primaquine/chloroquine and were confined to vertigo and headache (Table [2](#Tab2){ref-type="table"}). There was a trend for both vertigo and headache to occur more frequently at the higher tafenoquine doses. However, at the tafenoquine 600 mg single-dose, the incidence of vertigo was similar to that of primaquine/chloroquine and the incidence of headache was lower at all tafenoquine doses versus primaquine/chloroquine (Table [2](#Tab2){ref-type="table"}).Table 2Frequency of NPAEs with high-dose tafenoquine/chloroquine in vivax malaria patients \[[@CR81]\]Adverse event, n (%)Tafenoquine\
300 mg q.d. × 7 days (N = 18)Tafenoquine\
600 mg q.d. × 3 days (N = 19)Tafenoquine\
600 mg single dose (N = 18)Primaquine\
15 mg q.d. × 14 days (N = 12)Any NPAE8 (44)8 (42)4 (22)6 (50)Vertigo8 (44)8 (42)4 (22)3 (25)Headache4 (22)4 (21)2 (11)4 (33)

Single-dose tafenoquine/chloroquine {#Sec13}
-----------------------------------

Based on the need to co-administer a blood schizonticide, three comparative clinical studies have been conducted with single-dose tafenoquine plus standard 3-day chloroquine in *P. vivax* relapse prevention in centres across Asia, South America and Africa.DETECTIVE Phase 2b (TAF112582 part 1): a multicentre, phase 2b, double-blind, placebo-controlled, randomized, dose-selection study of single-dose tafenoquine (50, 100, 300, 600 mg) plus standard 3-day chloroquine versus placebo plus standard 3-day chloroquine or primaquine 15 mg for 14 days plus standard 3-day chloroquine \[[@CR9]\].DETECTIVE Phase 3 (TAF112582 part 2): a multicentre, phase 3 pivotal, double-blind, double-dummy, randomized placebo-controlled clinical trial of single-dose tafenoquine 300 mg plus standard 3-day chloroquine versus placebo plus standard 3-day chloroquine or primaquine 15 mg for 14 days plus standard 3-day chloroquine \[[@CR10]\].GATHER (TAF116564): a multicentre, phase 3 supportive, double-blind, double-dummy, parallel group, randomized trial of single-dose tafenoquine 300 mg plus standard 3-day chloroquine versus primaquine 15 mg for 14 days plus standard 3-day chloroquine \[[@CR11]\].

There are some key aspects that need to be highlighted in the assessment of NPAE risk with tafenoquine in *P. vivax* relapse prevention in these studies. Firstly, patients were infected with *P. vivax* malaria and symptomatic. Secondly, tafenoquine was co-administered with standard 3-day chloroquine, and so evaluation of tafenoquine NPAEs is hampered by the absence of a true placebo arm with comparisons having to be made against either chloroquine alone or primaquine/chloroquine. Lastly, in all three clinical trials, *P. vivax* recurrence after day 29 resulted in retreatment with primaquine/chloroquine and so adverse events recorded after this point include adverse events associated with recurrence of malaria as well as those associated with the rescue therapy. As relapse was more frequent in the chloroquine alone group than with either of the 8-aminoquinolines, adverse events after day 29 were consequently more frequent with placebo/chloroquine than for the 8-aminoquinoline arms. Thus, only adverse events occurring before day 29 should be considered for comparison to the placebo/chloroquine arm.

To further investigate whether an NPAE signal might be present in the safety database from these studies, an expanded definition of NPAEs was applied. As well as including the standard terms included under 'nervous system disorders' and 'psychiatric disorders', the expanded definition added labyrinthitis, vertigo, vestibular disorder, asthenia, fatigue, and alcohol intolerance to include terms with possible reference to vestibulocochlear function, which has its seat in the brainstem. This was considered important, considering the eighth cranial nerve appeared to have been affected adversely by some earlier quinoline molecules \[[@CR82], [@CR83]\].

### Tafenoquine/chloroquine dose ranging {#Sec14}

The DETECTIVE 2b study was designed to select the clinical regimen for tafenoquine/chloroquine in *P. vivax* relapse prevention and so was conducted in malaria patients \[[@CR9]\]. The most common NPAEs with tafenoquine/chloroquine at all doses were headache and dizziness, though at the highest tafenoquine dose of 600 mg, these occurred less frequently than with placebo/chloroquine. All other NPAEs were infrequent (Table [3](#Tab3){ref-type="table"}). There was no evidence of any dose--response for any NPAE (Table [3](#Tab3){ref-type="table"}).Table 3Frequency of NPAEs in *P. vivax* malaria patients given tafenoquine/chloroquine, primaquine/chloroquine or placebo/chloroquine \[[@CR9]\]Adverse event, n (%)TQ + CQPQ + CQ (N = 50)Placebo + CQ (N = 54)50 mg (N = 55)100 mg (N = 57)300 mg (N = 57)600 mg (N = 56)Any nervous system disorder17 (31)17 (30)13 (23)16 (29)17 (34)21 (39) Headache14 (25)17 (30)10 (18)16 (29)14 (28)20 (37) Dizziness7 (13)2 (4)5 (9)4 (7)5 (10)5 (9) Migraine000001 (2) Tremor001 (2)1 (2)00 Paraesthesia0001 (2)00 Sciatica01 (2)0000 Burning sensation1 (2)00000 Syncope00001 (2)0 Dysaesthesia00001 (2)0Any psychiatric disorder2 (4)3 (5)5 (9)3 (5)1 (2)1 (2) Insomnia2 (4)3 (5)5 (9)3 (5)3 (6)1 (2) Tic0001 (2)00Expanded terms^a^ Asthenia5 (9)4 (7)1 (2)5 (9)00 Fatigue01 (2)1 (2)000*CQ* chloroquine, *PQ* primaquine, *TQ* tafenoquine^a^Expanded terms: labyrinthitis, vertigo, vestibular disorder, asthenia, fatigue, and alcohol intolerance were also considered with possible reference to vestibulocochlear function

### Tafenoquine/chloroquine versus placebo/chloroquine {#Sec15}

DETECTIVE Phase 2b and DETECTIVE Phase 3 were placebo-controlled randomized studies designed as a seamless Phase 2b/3 programme, with similar protocols allowing data to be pooled for the single tafenoquine 300 mg therapeutic dose \[[@CR9], [@CR10]\]. All patients in the tafenoquine and placebo groups received 3-day chloroquine started on day 1; tafenoquine or placebo was given on day 1 or 2. Across the two studies, the overall prevalence of any nervous system disorders occurring before day 29 of the study was 11.4% (36/317) with tafenoquine/chloroquine and 10.2% (19/187) with placebo/chloroquine; psychiatric adverse events occurred in 3.8% (12/317) and 2.7% (5/187) of patients, respectively (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Neuropsychiatric adverse events occurring before day 29 in *P. vivax* patients given tafenoquine/chloroquine versus placebo/chloroquine \[[@CR9], [@CR10]\]

For individual adverse events, only headache and dizziness occurred in more than 5% of patients, with a trend for a higher incidence of dizziness and lower incidence of headache with tafenoquine/chloroquine versus placebo/chloroquine, though 95% CIs overlapped in both cases (Fig. [3](#Fig3){ref-type="fig"}). Psychiatric adverse events were confined to insomnia and anxiety at low prevalence in both treatment arms (Fig. [3](#Fig3){ref-type="fig"}). In these well-controlled randomized studies, none of the NPAEs identified led to study withdrawal or therapy interruption and there were no NPAEs classified as serious or severe. These results suggest a favourable NPAE profile for tafenoquine/chloroquine, similar to that of chloroquine alone, with a low prevalence of events of mild-to-moderate severity.

### Tafenoquine/chloroquine versus primaquine/chloroquine {#Sec16}

Primaquine/chloroquine was included as a comparator in the DETECTIVE Phase 2b, DETECTIVE Phase 3 and GATHER studies \[[@CR9]--[@CR11]\]. All three studies had similar protocols and all used the standard primaquine dose of 15 mg/day for 14 days. Across the three studies, the overall prevalence of any nervous system disorders occurring before day 29 was 15.5% (75/483) with tafenoquine/chloroquine and 13.3% (35/264) with primaquine/chloroquine; psychiatric adverse events occurred in 2.9% (14/483) and 3.4% (9/264) of patients, respectively (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Neuropsychiatric adverse events occurring before day 29 in *P. vivax* patients given tafenoquine/chloroquine versus primaquine/chloroquine \[[@CR9]--[@CR11]\]

As was seen for the comparison versus placebo, for both tafenoquine/chloroquine and primaquine/chloroquine, only dizziness and headache occurred in \> 5% of patients, and with a similar prevalence for both comparators (Fig. [4](#Fig4){ref-type="fig"}). Psychiatric adverse events were confined to insomnia and anxiety at low prevalence in both treatment arms (Fig. [4](#Fig4){ref-type="fig"}). None of the NPAEs identified led to study withdrawal or therapy interruption and there were no NPAEs classified as serious or severe.

When examining the frequency of all adverse events occurring over the 6-month study duration, there was no evidence of any increased risk for NPAEs with tafenoquine/chloroquine versus primaquine/chloroquine (Table [4](#Tab4){ref-type="table"}). As would be expected given the longer follow up period, the frequency of NPAEs in both arms was higher after 6 months of follow up (Table [4](#Tab4){ref-type="table"}) versus day 29 (Fig. [4](#Fig4){ref-type="fig"}), but there were no differences between the treatment groups. Nervous system adverse events occurred in 21.7% (105/483) of patients in the tafenoquine/chloroquine group and 22.7% (60/264) in the primaquine/chloroquine group; psychiatric adverse events occurred in 3.1% (15/483) and 4.5% (12/264), respectively. None of the NPAEs identified in the tafenoquine/chloroquine group led to study withdrawal or therapy interruption and there were no NPAEs classified as serious or severe. These results suggest an NPAE profile for tafenoquine/chloroquine similar to that of primaquine/chloroquine, with a low prevalence of NPAEs of mild-to-moderate severity.Table 4Frequency of all NPAEs occurring with tafenoquine/chloroquine versus primaquine/chloroquine (day 1 to day 180) \[[@CR9]--[@CR11]\]Event---n (%) patientsGrade^a^Integrated safety summaryTafenoquine (N = 483)Primaquine (N = 264)Nervous system disordersAny105 (22)60 (23)Grade 178 (16)38 (14)Grade 226 (5)19 (7)*Grade 302 (\< 1)*NA1 (\< 1)1 (\< 1) HeadacheAny64 (13)40 (15)Grade 145 (9)22 (8)Grade 218 (4)16 (6)*Grade 302 (\< 1)*NA1 (\< 1)0 DizzinessAny59 (12)30 (11)Grade 152 (11)25 (9)Grade 27 (1)4 (2)NA01 (\< 1) MigraineAny3 (\< 1)1 (\< 1)Grade 12 (\< 1)0Grade 21 (\< 1)1 (\< 1) SyncopeAny2 (\< 1)1 (\< 1)Grade 11 (\< 1)1 (\< 1)Grade 21 (\< 1)0 Balance disorderAny1 (\< 1)0Grade 21 (\< 1)0 SomnolenceAny1 (\< 1)0Grade 21 (\< 1)0 TremorAny1 (\< 1)1 (\< 1)Grade 11 (\< 1)1 (\< 1) Burning sensationAny01 (\< 1)Grade 101 (\< 1) DysaesthesiaAny01 (\< 1)Grade 101 (\< 1) HypoaesthesiaAny01 (\< 1)Grade 201 (\< 1)Psychiatric disordersAny15 (3)12 (5)Grade 19 (2)7 (3)Grade 26 (1)5 (2) InsomniaAny15 (3)8 (3)Grade 19 (2)4 (2)Grade 26 (1)4 (2) AnxietyAny2 (\< 1)3 (1)Grade 102 (\< 1)Grade 22 (\< 1)1 (\< 1) DepressionAny01 (\< 1)Grade 101 (\< 1)Expanded definition of NPAEs AstheniaAny8 (2)5 (2)Grade 17 (1)2 (\< 1)Grade 21 (\< 1)3 (1) FatigueAny3 (\< 1)0Grade 13 (\< 1)0 LabyrinthitisAny2 (\< 1)0Grade 12 (\< 1)0 Alcohol intoleranceAny1 (\< 1)0Grade 11 (\< 1)0 VertigoAny3 (\< 1)1 (\< 1)Grade 12 (\< 1)1 (\< 1)Grade 21 (\< 1)0 Vestibular disorderAny1 (\< 1)0Grade 11 (\< 1)0Data are from the DETECTIVE phase 2b, DETECTIVE phase 3, and GATHER trials (safety population). Vivax malaria patients were treated with chloroquine plus either single-dose tafenoquine 300 mg or primaquine 15 mg for 14 days. Adverse events of Grade 3 and above in any treatment group are italicizedNote that this includes adverse events that were associated with recurrences after day 29. Subjects that experienced recurrence received further treatment with primaquine. Thus, the comparison of adverse events before day 29 provides a more reliable indicator of potential differences caused by drug treatment (see Fig. [4](#Fig4){ref-type="fig"})^a^Common Terminology Criteria for Adverse Events v4.0

Tafenoquine safety database analysis {#Sec17}
====================================

An analysis of all tafenoquine clinical safety data available to GlaxoSmithKline (all studies safety database) was conducted to support review by the US Food and Drug Administration \[[@CR74]\]. This included healthy volunteers, *P. vivax* patients receiving tafenoquine/chloroquine and those receiving tafenoquine prophylaxis. Overall, 4131 tafenoquine-exposed subjects were included compared to 792 who received placebo/chloroquine or placebo \[[@CR74]\]. Comparing across these results is difficult as treatment and prophylaxis studies would be expected to have differing adverse event profiles, both in the active and the placebo arms. However, overall there was no evidence that tafenoquine/chloroquine 300 mg for ≤ 3 days had an increased risk of NPAEs versus placebo (Table [5](#Tab5){ref-type="table"}). There were no serious, severe or medically important NPAEs (0/807) identified in any of the studies in which tafenoquine was given at 300 mg for ≤ 3 days.Table 5Adverse events classified as nervous system disorders or psychiatric disorders reported across the entire tafenoquine development programme classified by total tafenoquine dose \[[@CR74]\]Adverse event, n (%)All placebo^a^ (N = 794)Total TQ 300 mg ≤ 3 days (N = 807)Total TQ \> 300 mg ≤ 3 days (N = 1482)Total TQ \> 300 mg \> 3 days (N = 1445)All TQ^b^ (N = 4129)Any nervous system disorder170 (21)142 (18)240 (16)269 (19)734 (18) Headache149 (19)98 (12)164 (11)211 (15)544 (13) Migraine4 (\< 1)3 (\< 1)03 (\< 1)8 (\< 1) Sinus headache1 (\< 1)004 (\< 1)4 (\< 1) Tension headache0002 (\< 1)2 (\< 1) Head discomfort001 (\< 1)01 (\< 1) Visual field defect0001 (\< 1)1 (\< 1) Lethargy0028 (2)28 (2)56 (1) Somnolence1 (\< 1)3 (\< 1)21 (1)1 (\< 1)25 (\< 1) Amnesia0001 (\< 1)1 (\< 1) Depressed level of consciousness01 (\< 1)001 (\< 1) Disturbance in attention001 (\< 1)01 (\< 1) Dysgeusia1 (\< 1)017 (1)1 (\< 1)18 (\< 1) Paraesthesia003 (\< 1)4 (\< 1)8 (\< 1) Hypoaesthesia1 (\< 1)03 (\< 1)1 (\< 1)4 (\< 1) Hyperaesthesia0001 (\< 1)2 (\< 1) Burning sensation00001 (\< 1) Coordination abnormal0002 (\< 1)2 (\< 1) Balance disorder01 (\< 1)001 (\< 1) Dizziness24 (3)62 (8)56 (4)33 (2)171 (4) Syncope02 (\< 1)1 (\< 1)2 (\< 1)5 (\< 1) Presyncope0001 (\< 1)1 (\< 1) Dizziness postural1 (\< 1)0000 Loss of consciousness1 (\< 1)0000 Tremor01 (\< 1)1 (\< 1)2 (\< 1)4 (\< 1) Muscle contractions involuntary001 (\< 1)01 (\< 1) Sciatica0002 (\< 1)3 (\< 1) Post herpetic neuralgia001 (\< 1)1 (\< 1)2 (\< 1) Trigeminal neuralgia0001 (\< 1)1 (\< 1)Any psychiatric disorder8 (1)16 (2)19 (1)37 (3)79 (2) Insomnia8 (1)15 (2)12 (\< 1)15 (1)48 (1) Abnormal dreams01 (\< 1)06 (\< 1)7 (\< 1) Sleep disorder0003 (\< 1)3 (\< 1) Nightmare0002 (\< 1)2 (\< 1) Agitation0002 (\< 1)2 (\< 1) Anxiety02 (\< 1)002 (\< 1) Anxiety disorder0002 (\< 1)2 (\< 1) Irritability001 (\< 1)02 (\< 1) Neurosis0001 (\< 1)1 (\< 1) Panic attack0001 (\< 1)1 (\< 1) Psychotic disorder001 (\< 1)01 (\< 1) Stress0001 (\< 1)1 (\< 1) Euphoric mood001 (\< 1)2 (\< 1)3 (\< 1) Depressed mood001 (\< 1)1 (\< 1)2 (\< 1) Depression0002 (\< 1)2 (\< 1) Bipolar disorder0001 (\< 1)1 (\< 1) Disinhibition001 (\< 1)01 (\< 1) Mood altered001 (\< 1)01 (\< 1) Alcoholic hangover0001 (\< 1)1 (\< 1) Tic001 (\< 1)01 (\< 1)^a^The placebo group includes healthy volunteers treated with placebo and *P. vivax* subjects treated with chloroquine alone in *P. vivax* relapse prevention^b^Also includes 392 subjects who received \< 300 mg total dose and 3 subjects who received 300 mg total dose \> 3 days

The tafenoquine all studies safety database (Table [5](#Tab5){ref-type="table"}), plus data from five previous clinical pharmacology studies conducted by the US Army were reviewed for serious or severe psychiatric disorders or medically important events. Nine subjects were identified, five with depression, three with psychosis and one with suicidal behaviour (Table [6](#Tab6){ref-type="table"}). Only one case of depression occurred in a *P. vivax* patient; this individual had a history of depression. Three of the other four subjects with depression had no previous history of psychiatric illness or predisposing medical conditions. However, all four subjects with psychosis or suicidal behaviour had relevant previous psychiatric histories. Whether these events represented the underlying psychiatric conditions of the subjects or whether their symptoms were triggered or worsened by tafenoquine cannot be conclusively determined. Thus, for tafenoquine prophylaxis the precautionary recommendation is that the drug is not given to those with a history of psychotic disorders, or who currently have psychotic symptoms, including hallucinations (seeing or hearing things that are not really there), delusions (false or strange thoughts or beliefs), or disorganized thinking or behaviour \[[@CR84]\]. This is not the case for single-dose tafenoquine for *P. vivax* relapse prevention, although it is recommended that a careful medical history be taken to identify any pre-existing mental health problems \[[@CR85]\].Table 6Details of subjects with severe, serious or medically important psychiatric adverse events following tafenoquine \[[@CR74]\]Study identification (indication) \[refs.\]Study designDoseEvent preferred term (severity or verbatim terms)OnsetDurationResolutionRelationship to study drug by the InvestigatorIntervention/action takenMedical historySB252263/043 (prophylaxis) \[[@CR89]\]R, DB, PC750 mg cumulativeSuicidal behaviour (associated with alcohol intoxication)^a^Day 81 day after tafenoquine discontinuedResolvedRelated (chloroquine co-suspect)^b^Hospitalized and required corrective therapy (intervention unknown)/withdrawn due to unstable mental stateFamily reported history of marital difficulties and previous suicide threat; no other relevant history or concomitant medications reported at screeningSB252263/050 subject A (volunteers) \[[@CR90]\]R, DB, PC350 mg single doseAcute psychotic episode (severe)Day 2425 daysRecoveredPossibly relatedHospitalized following progressive emotional distressTwo previous episodes of psychosis (not disclosed at screening)SB252263/050 subject B (volunteers) \[[@CR90]\]R, DB, PC500 mg single dosePsychotic episode (severe)Day 89 daysRecoveredRemotely relatedHospitalized for a pre-scheduled psychiatric admissionRecent diagnosis of schizophrenia (not disclosed at screening)SB252263/014 (volunteers) \[unpublished\]R, O, PG1200 mg cumulativeParanoid hallucinotic psychosis (serious)Day 273 daysNot resolvedUnrelatedHospitalized and treated with olanzapine and lorazepam/noneHistory of "hallucinotic psychosis" 6 months earlier (not disclosed at screening); no obvious signs of psychosis at screening; negative drug screenTAF112582 part 1 (*P. vivax* relapse prevention) \[[@CR9]\]R, DB, PC600 mg single doseDepressed moodDay 6UnknownResolvedUnrelated (chloroquine co-suspect)^b^Hospitalized (on day 88 for 2 days) with nausea, epigastric pain, diarrhoea, and depression; treated with fluoxetine; consulted with psychiatric specialist (findings unknown)History of depression but no suicidal tendencies; irregular psychiatric consults; frequent but irregular use of diazepam (10 mg)TAF114582 (volunteers) \[[@CR91]\]R, SB, PC, AC600 mg single doseDepressed mood (mild)Day 43 daysResolvedRelatedNoneNo relevant past medical history or concomitant medications were reported; at the time of the event, subject also reported abdominal pain, diarrhoea, and palpitationsSB252263/033 (prophylaxis) \[[@CR7]\]R, DB, AC1200 mg cumulativeDepression (moderate)Day 2487 daysResolvedRelatedRequired corrective therapy (paroxetin)/withdrawn from studyClosed head injury 3 years prior to studySB252263/057 subject B (volunteers) \[[@CR92]\]R, DB, PC1600 mg cumulativeDepressed mood (mild)Day 3715 daysResolvedUnlikely relatedNoneNo relevant past history; treated for a UTI with sulfamethoxazole starting on day 13 (co-suspect)SB252263/057 subject A (volunteers) \[[@CR92]\]R, DB, PC5200 mg^c^ cumulativeBipolar depression (mild); depression (mild)Day 223 (62 days since last dose)Lost to follow-upUnknownUnlikely relatedBupropion and lithium started on study day 223 (ongoing)/excluded due to a positive hepatitis/HIV screenNo relevant past history or concomitant medications*UTI* urinary tract infection, *R* randomised, *SB* single blind, *DB* double blind, *PC* placebo controlled, *AC* active controlled, *O* open label, *PG* parallel group^a^Family reported that subject had taken "poison." The event was not assigned a body system and therefore does not appear in the pooled output for adverse events within the psychiatric disorders classification^b^The sponsor considered chloroquine co-suspect^c^Loading dose 200 mg/day for 3 days plus 200 mg weekly for 23 weeks

Tafenoquine prophylaxis {#Sec18}
-----------------------

Although this review focuses on tafenoquine for *P. vivax* relapse prevention, it is necessary to briefly discuss the prophylaxis studies as there are some features of these that should be explained in order to understand the safety signals for NPAEs at higher tafenoquine exposures.

In Table [5](#Tab5){ref-type="table"}, 1445 patients received prophylaxis at the highest tafenoquine doses of \> 300 mg \> 3 days. However, 34.0% (492/1445) of subjects in the highest dose group were Australian Defence Force (ADF) personnel deployed on United Nations peacekeeping duties in East Timor, many of whom experienced a 'war-like' scenario \[[@CR54]\]. A recent examination compared data for ADF subjects deployed in East Timor to non-ADF resident subjects who received the same tafenoquine regimen (200 mg loading dose for 3 days, then 200 mg weekly prophylaxis) \[[@CR54]\]. In this analysis, all adverse events were more common in the deployed ADF group (467/492; 94.9%) than in resident non-ADF subjects (225/333; 67.6%), and psychiatric adverse events occurred in 5.1% (25/492) of ADF soldiers versus 2.1% (7/333) of resident non-ADF subjects \[[@CR54], [@CR79]\].

A possible explanation for this increased reporting of NPAEs in ADF personnel is that soldiers experienced traumatic events, including danger of being killed or injured (71%); seeing dead bodies (49%); fear of exposure to a toxic agent, contagious disease, or injury (31%); and having a friend/associate killed or injured (30%) \[[@CR86]\]. Additionally, around 40% of soldiers who received tafenoquine sustained physical injuries as a result of their deployment while other illnesses, such as gastroenteritis and heat-related illnesses, were also common \[[@CR54]\]. Thus, over the 6 months of tafenoquine administration, soldiers were exposed to many factors, other than tafenoquine, that could have contributed to their reporting of NPAEs and which confound causality assessment. Thus, the higher incidence of NPAEs at higher tafenoquine exposures not only reflects the long duration over which adverse events were recorded, but also the circumstances in which the drug was taken.

Conclusions {#Sec19}
===========

There was no evidence of neurotoxicity, neurobehavioural disorder, or clinical neurotoxicity with tafenoquine at supra-therapeutic doses in rodent and non-rodent models \[[@CR74]--[@CR79]\]. These observations, along with the demonstration of minimal CNS penetration in the rat suggest that serious or severe CNS events are unlikely to occur with tafenoquine therapeutic doses in humans.

In *P. vivax* relapse prevention, with single-dose tafenoquine (300 mg)/chloroquine, no serious or severe CNS events were reported with the observed events being mild-to-moderate and self-limiting \[[@CR9]--[@CR11]\]. Tafenoquine/chloroquine did not increase the prevalence of NPAEs compared with placebo/chloroquine and the nature and frequency of NPAEs with tafenoquine/chloroquine were similar to that of primaquine/chloroquine \[[@CR9]--[@CR11]\]. Therefore, single-dose 300 mg tafenoquine/chloroquine for *P. vivax* malaria relapse prevention is anticipated to have a low risk of significant CNS effects \[[@CR74]\]. However, it is recommended that patients disclose any prior mental health issues prior to tafenoquine prescribing.

In clinical trials, tafenoquine/chloroquine has been shown to reduce the risk of *P. vivax* relapse by approximately 70% over 6 months' follow up compared with chloroquine alone, with a similar safety profile to primaquine \[[@CR9]--[@CR11], [@CR87]\]. Single-dose tafenoquine offers complete adherence and presents an opportunity to expand *P. vivax* relapse prevention and improve clinical effectiveness over the current 14-day primaquine regimen \[[@CR88]\]. Tafenoquine is now under evaluation with blood schizonticides other than chloroquine for relapse prevention in *P. vivax*.

Coupled with advances in rapid quantitative diagnostics for screening of patients for glucose-6-phosphate dehydrogenase deficiency, a contraindication for 8-aminoquinoline therapy, the risk:benefit profile for tafenoquine in *P. vivax* relapse prevention is favourable. The potential of tafenoquine for both reducing the burden of *P. vivax* malaria and draining the hypnozoite malaria transmission reservoir represents the first major advance in the treatment and control of *P. vivax* since primaquine was introduced nearly 70 years ago.

NPAE

:   Neuropsychological adverse events

ADF

:   Australian Defence Force
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